Matches in SemOpenAlex for { <https://semopenalex.org/work/W2968487989> ?p ?o ?g. }
- W2968487989 endingPage "2688" @default.
- W2968487989 startingPage "2688" @default.
- W2968487989 abstract "Background: Recently, a comprehensive high-throughput sequencing study of pediatric and adult core-binding factor (CBF) AML [t(8;21), n=85; inv(16), n=80] provided novel aspects of the genetic heterogeneity and disease biology of t(8;21) AML (Faber et al. Nat Genet 2016). In addition to well-established variants in genes encoding for proteins in tyrosine kinase (TK)/RAS signaling, epigenetic regulation (ER), and in the cohesin complex (CC), novel candidate genes were identified. Aims: We aimed to validate and to further extend recent findings by comprehensive profiling of the mutational spectrum of t(8;21) AML using a high-throughput targeted sequencing (HTS) approach. Methods: HTS was performed of the entire coding region of 244 genes with evidence in hematological malignancies. Pretreatment peripheral blood or bone marrow specimens of 143 adult t(8;21) AML patients (pts) were analyzed. 114/143 pts were enrolled in seven prospective AMLSG treatment trials. Libraries (total probes size: 1.36 Mbp) were prepared using SureSelectXT custom solutions (Agilent). Paired-end sequencing was carried out on a HiSeq platform (Illumina). Results: A mean on-target sequencing depth of 900x was obtained for all pts. Coding variants without known SNP annotation and with a minimum variant allele fraction (VAF) of 5% were called. In sum 756 mutations (missense: 70%; indels: 19%; nonsense: 9%; other: 2%) were detected with an average of 5.3 per pt (SD: ±2.5). 99% of pts harbored at least 1 mutation and 90% 3 or more. In line with previous studies, activating mutations in TK/RAS signaling pathways represented recurrent events: KIT (34/143; 24%), NRAS (24/143; 17%), FLT3 (15/143; 10%; point mutations only), and KRAS (4/143; 3%).In addition to these mutations conferring proliferative clonal advantage, a striking enrichment of mutations was observed in genes involved in histone modification and DNA methylation, ASXL2 (22/143; 15%), ASXL1 (21/143; 15%), KDM6A (14/143; 10%), EZH2 (11/143; 8%), CREBBP (8/143; 6%), SRCAP (8/143; 6%), TET2 (19/143; 13%) and DNMT3A (9/143; 6%), emphasizing their contribution to impairing differentiation in this leukemia subtype. Further, frequent aberrations were found in the cohesin genes that are involved in sister chromatid segregation during mitosis and DNA repair: RAD21 (17/143; 12%), SMC1A (10/143; 7%), STAG2 (5/143; 3%), and SMC3 (5/143; 3%). In general, mutations in genes belonging to the same functional subgroups were rarely co-occurring suggesting functional redundancy without additional synergistic effect. We also identified recurrent variants in previously detected candidate genes outside these functional clusters. A remarkably high incidence of loss of function mutations was found in the ZBTB7A gene(27/143; 19%), encoding for a transcription factor guiding hematopoietic lineage fate. Recurrent mutations were also observed in CCND2 (14/143; 10%) , involved in hematopoietic cell proliferation, MGA (11/143; 8%), a negative regulator of MYC, as well as DHX15 (10/143; 7%), associated with ribosome biogenesis and spliceosome function. When focusing on the clonal hierarchy we found that the median VAF in genes belonging to ER and CC (0.31; range 0.3-0.91; 0.35, range 0.05-0.96; respectively) was higher than in genes associated with TK/RAS signaling (0.16, range 0.05-0.53) suggesting that mutations affecting the epigenetic state and differentiation occur earlier than those impairing proliferation during development of t(8;21) AML. Conclusion: Using a comprehensive sequencing approach we could further delineate the molecular pattern of t(8;21) AML that despite shared genetic lesions is remarkably different to inv(16) AML. Here, mutation clusters in genes involved in TK/RAS signaling, ER and CC were confirmed as well as novel t(8;21)-associated gene mutations such as in ZBTB7A and CCND2 that play an essential role in regulation of hematopoietic cell proliferation and differentiation. Further analyses including sample size extension as well as correlation of findings with clinical parameters are ongoing. Disclosures Dohner: Astex Pharmaceuticals: Honoraria, Membership on an entity9s Board of Directors or advisory committees, Research Funding; Sunesis: Honoraria; Arog Pharmaceuticals: Honoraria, Research Funding; Pfizer: Research Funding; Abbvie: Honoraria; Celgene: Honoraria, Membership on an entity9s Board of Directors or advisory committees, Research Funding; Bristol Myers Squibb: Research Funding; Boehringer Ingelheim: Research Funding; Seattle Genetics: Honoraria; Agios: Honoraria; Amgen: Honoraria; Celator: Honoraria; Novartis: Honoraria, Membership on an entity9s Board of Directors or advisory committees, Research Funding. Dohner: Novartis: Honoraria, Research Funding." @default.
- W2968487989 created "2019-08-22" @default.
- W2968487989 creator A5007016021 @default.
- W2968487989 creator A5013231760 @default.
- W2968487989 creator A5018388015 @default.
- W2968487989 creator A5022178280 @default.
- W2968487989 creator A5030025370 @default.
- W2968487989 creator A5037133740 @default.
- W2968487989 creator A5040956966 @default.
- W2968487989 creator A5046034506 @default.
- W2968487989 creator A5050454200 @default.
- W2968487989 creator A5053311081 @default.
- W2968487989 creator A5053578678 @default.
- W2968487989 creator A5053949970 @default.
- W2968487989 creator A5053983155 @default.
- W2968487989 creator A5058195823 @default.
- W2968487989 creator A5065893901 @default.
- W2968487989 creator A5068674008 @default.
- W2968487989 creator A5069866186 @default.
- W2968487989 creator A5081437952 @default.
- W2968487989 creator A5081614049 @default.
- W2968487989 creator A5081804029 @default.
- W2968487989 creator A5089395073 @default.
- W2968487989 date "2017-12-07" @default.
- W2968487989 modified "2023-09-30" @default.
- W2968487989 title "Genetic Heterogeneity of t(8;21)(q22;q22.1) Acute Myeloid Leukemia Revealed By High-Throughput Targeted Sequencing" @default.
- W2968487989 doi "https://doi.org/10.1182/blood.v130.suppl_1.2688.2688" @default.
- W2968487989 hasPublicationYear "2017" @default.
- W2968487989 type Work @default.
- W2968487989 sameAs 2968487989 @default.
- W2968487989 citedByCount "0" @default.
- W2968487989 crossrefType "journal-article" @default.
- W2968487989 hasAuthorship W2968487989A5007016021 @default.
- W2968487989 hasAuthorship W2968487989A5013231760 @default.
- W2968487989 hasAuthorship W2968487989A5018388015 @default.
- W2968487989 hasAuthorship W2968487989A5022178280 @default.
- W2968487989 hasAuthorship W2968487989A5030025370 @default.
- W2968487989 hasAuthorship W2968487989A5037133740 @default.
- W2968487989 hasAuthorship W2968487989A5040956966 @default.
- W2968487989 hasAuthorship W2968487989A5046034506 @default.
- W2968487989 hasAuthorship W2968487989A5050454200 @default.
- W2968487989 hasAuthorship W2968487989A5053311081 @default.
- W2968487989 hasAuthorship W2968487989A5053578678 @default.
- W2968487989 hasAuthorship W2968487989A5053949970 @default.
- W2968487989 hasAuthorship W2968487989A5053983155 @default.
- W2968487989 hasAuthorship W2968487989A5058195823 @default.
- W2968487989 hasAuthorship W2968487989A5065893901 @default.
- W2968487989 hasAuthorship W2968487989A5068674008 @default.
- W2968487989 hasAuthorship W2968487989A5069866186 @default.
- W2968487989 hasAuthorship W2968487989A5081437952 @default.
- W2968487989 hasAuthorship W2968487989A5081614049 @default.
- W2968487989 hasAuthorship W2968487989A5081804029 @default.
- W2968487989 hasAuthorship W2968487989A5089395073 @default.
- W2968487989 hasConcept C104317684 @default.
- W2968487989 hasConcept C119054055 @default.
- W2968487989 hasConcept C132917006 @default.
- W2968487989 hasConcept C135763542 @default.
- W2968487989 hasConcept C141231307 @default.
- W2968487989 hasConcept C153209595 @default.
- W2968487989 hasConcept C501734568 @default.
- W2968487989 hasConcept C502942594 @default.
- W2968487989 hasConcept C51679486 @default.
- W2968487989 hasConcept C54355233 @default.
- W2968487989 hasConcept C75563809 @default.
- W2968487989 hasConcept C86803240 @default.
- W2968487989 hasConceptScore W2968487989C104317684 @default.
- W2968487989 hasConceptScore W2968487989C119054055 @default.
- W2968487989 hasConceptScore W2968487989C132917006 @default.
- W2968487989 hasConceptScore W2968487989C135763542 @default.
- W2968487989 hasConceptScore W2968487989C141231307 @default.
- W2968487989 hasConceptScore W2968487989C153209595 @default.
- W2968487989 hasConceptScore W2968487989C501734568 @default.
- W2968487989 hasConceptScore W2968487989C502942594 @default.
- W2968487989 hasConceptScore W2968487989C51679486 @default.
- W2968487989 hasConceptScore W2968487989C54355233 @default.
- W2968487989 hasConceptScore W2968487989C75563809 @default.
- W2968487989 hasConceptScore W2968487989C86803240 @default.
- W2968487989 hasLocation W29684879891 @default.
- W2968487989 hasOpenAccess W2968487989 @default.
- W2968487989 hasPrimaryLocation W29684879891 @default.
- W2968487989 hasRelatedWork W2293083112 @default.
- W2968487989 hasRelatedWork W2516343997 @default.
- W2968487989 hasRelatedWork W2558985317 @default.
- W2968487989 hasRelatedWork W2583023239 @default.
- W2968487989 hasRelatedWork W2587069367 @default.
- W2968487989 hasRelatedWork W2589831889 @default.
- W2968487989 hasRelatedWork W2594014462 @default.
- W2968487989 hasRelatedWork W2618268765 @default.
- W2968487989 hasRelatedWork W2751280413 @default.
- W2968487989 hasRelatedWork W2911016682 @default.
- W2968487989 hasRelatedWork W2952734728 @default.
- W2968487989 hasRelatedWork W2980183735 @default.
- W2968487989 hasRelatedWork W2980288845 @default.
- W2968487989 hasRelatedWork W2980651742 @default.
- W2968487989 hasRelatedWork W2980930249 @default.
- W2968487989 hasRelatedWork W2986197580 @default.
- W2968487989 hasRelatedWork W2989542823 @default.
- W2968487989 hasRelatedWork W2990830108 @default.